Salarius Pharmaceuticals Board Shake-up
Ticker: DCOY · Form: 8-K · Filed: Aug 18, 2025 · CIK: 1615219
Sentiment: neutral
Topics: board-change, management-change
TL;DR
Salarius board sees new faces as Vaught exits; Chew and Smith join.
AI Summary
Salarius Pharmaceuticals, Inc. announced on August 17, 2025, a change in its board of directors. Specifically, Dr. Jeffrey T. Vaught has resigned from his position as a director, effective August 15, 2025. The company has also appointed two new directors, Dr. David M. E. Chew and Mr. Robert L. W. Smith, to its board.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes can introduce uncertainty regarding strategic direction and leadership stability.
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- Dr. Jeffrey T. Vaught (person) — Resigning Director
- August 15, 2025 (date) — Effective date of resignation
- Dr. David M. E. Chew (person) — Newly Appointed Director
- Mr. Robert L. W. Smith (person) — Newly Appointed Director
- August 17, 2025 (date) — Date of report
FAQ
Who resigned from the Salarius Pharmaceuticals board of directors?
Dr. Jeffrey T. Vaught resigned from the board of directors.
When was Dr. Jeffrey T. Vaught's resignation effective?
Dr. Jeffrey T. Vaught's resignation was effective August 15, 2025.
Who were appointed as new directors to the Salarius Pharmaceuticals board?
Dr. David M. E. Chew and Mr. Robert L. W. Smith were appointed as new directors.
What is the exact name of the company filing this report?
The exact name of the company is Salarius Pharmaceuticals, Inc.
On what date was this 8-K filing reported?
This 8-K filing was reported on August 17, 2025.
Filing Stats: 843 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2025-08-18 08:33:54
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi
Filing Documents
- flks-20250817.htm (8-K) — 29KB
- 0001615219-25-000107.txt ( ) — 144KB
- flks-20250817.xsd (EX-101.SCH) — 2KB
- flks-20250817_lab.xml (EX-101.LAB) — 22KB
- flks-20250817_pre.xml (EX-101.PRE) — 13KB
- flks-20250817_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: August 18, 2025 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Executive Vice President & Chief Financial Officer